Ignite Creation Date:
2024-05-05 @ 11:58 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00192348
Status:
COMPLETED
Last Update Posted:
2021-09-13
First Post:
2005-09-12
Brief Title:
A Prospective Randomized Double-Blind Placebo-Controlled Trial to Assess the Safety and Tolerability of Influenza Virus VaccineCAIV-T in Healthy Infants
Sponsor:
MedImmune LLC
Organization:
MedImmune LLC
Study Overview
Official Title:
A Prospective Randomized Double-Blind Placebo-Controlled Trial to Assess the Safety and Tolerability of Influenza Virus Vaccine Trivalent Types A B Live Cold Adapted CAIV-T in Healthy Infants
Status:
COMPLETED
Status Verified Date:
2006-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Trial to compare the safety and tolerability of one and two doses of influenza virus vaccine
Detailed Description:
The objective of this study was to compare the safety and tolerability of one and two doses of influenza virus vaccine trivalent types A and B live cold-adapted liquid CAIV-T with placebo when administered intranasally to healthy infants aged 6 24 weeks
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None